One researcher (Dr. K. Hashimoto) has a pending patent for "Application of R-ketamine and salt thereof as pharmaceuticals" by Chiba Univesity, and has received research support by Otsuka, Sumitomo-Dainippon, and Taisho pharmaceutical companies.
|HAM-D||25.20 +- 5.75||26.15 +- 6.56||23.95 +- 4.37||26.85 +- 4.06|
|HAM-A||10.35 +- 2.18||11.30 +- 2.60||10.95 +- 2.63||10.65 +- 2.01|
|MADRS||26.90 +- 5.71||28.20 +- 6.84||26.00 +- 4.65||28.90 +- 4.19|
Primary outcome (HAM-D)
Results indicate that ethosuximide does not have antidepressant actions in non-medicated patients with MDD
It seems that antidepressant-like effects of ethosuximide are limited to WAG/Rij rats, which suggests a link between absence seizures and depressive-like behaviours in this strain of rats.
We could not find any antidepressant effect of ethosuximide on the clinician-reported HAM-D and MADRS scores after single and repeated oral administration. Therefore, it is unlikely that ethosuximide elicits ketamine-like rapid-acting antidepressant actions in patients with MDD, but the negative findings need to be replicated by other research groups.
Results appropriately interpreted
No change at this point